Antiviral Drug Market Size, Share, Growth, and Industry Analysis, By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors); By Application (HIV, Hepatitis, Influenza), Regional Insights; and Forecast to 2034

Table of Contents

1. Executive Summary
   1. Introduction
2. Market Introduction
   1. Market Definition
   2. Scope of the Study
   3. Market Structure
3. Research Methodology
   1. Primary Research
   2. Research Methodology
   3. Assumptions & Exclusions
   4. Secondary Data Sources
4. Market Factor Analysis
   1. Value Chain Analysis: Antiviral Drug Market
   2. Porters Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitution
      4. Threat of New Entrants
      5. Competitive Rivalry
5. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
6. Recent Trends Analysis
7. Impact of COVID-19 on Antiviral Drug Market
   1. Pre and Post Covid -19 Market Scenario Analysis
   2. Market Recovery Timeline and Challenge
   3. Measures Taken by Top Players
8. Regulatory Landscape
9. Antiviral Drug Market, Drug Class
   1. Introduction
      1. Market Size and Forecast, Drug Class
   2. DNA Polymerase Inhibitors
      1. Market Size and Forecast, By Region
   3. Reverse Transcriptase Inhibitors
      1. Market Size and Forecast, By Region
   4. Protease Inhibitors
      1. Market Size and Forecast, By Region
10. Antiviral Drug Market, Application
    1. Introduction
       1. Market Size and Forecast, Application
    2. HIV
       1. Market Size and Forecast, By Region
    3. Hepatitis
       1. Market Size and Forecast, By Region
    4. Influenza
       1. Market Size and Forecast, By Region
11. Regional Overview
    1. Introduction
       1. Market Size and Forecast
    2. North America
       1. Market Size and Forecast
          1. Drug Class
             1. DNA Polymerase Inhibitors
             2. Reverse Transcriptase Inhibitors
             3. Protease Inhibitors
          2. Application
             1. HIV
             2. Hepatitis
             3. Influenza
       2. U.S.
          1. Drug Class
             1. DNA Polymerase Inhibitors
             2. Reverse Transcriptase Inhibitors
             3. Protease Inhibitors
          2. Application
             1. HIV
             2. Hepatitis
             3. Influenza
       3. Canada
    3. Europe
       1. Market Size and Forecast
          1. Drug Class
             1. DNA Polymerase Inhibitors
             2. Reverse Transcriptase Inhibitors
             3. Protease Inhibitors
          2. Application
             1. HIV
             2. Hepatitis
             3. Influenza
       2. U.K.
          1. Drug Class
             1. DNA Polymerase Inhibitors
             2. Reverse Transcriptase Inhibitors
             3. Protease Inhibitors
          2. Application
             1. HIV
             2. Hepatitis
             3. Influenza
       3. Germany
       4. France
       5. Spain
       6. Italy
       7. Russia
       8. Nordic
       9. Benelux
       10. Rest of Europe
    4. APAC
       1. Market Size and Forecast
          1. Drug Class
             1. DNA Polymerase Inhibitors
             2. Reverse Transcriptase Inhibitors
             3. Protease Inhibitors
          2. Application
             1. HIV
             2. Hepatitis
             3. Influenza
       2. China
          1. Drug Class
             1. DNA Polymerase Inhibitors
             2. Reverse Transcriptase Inhibitors
             3. Protease Inhibitors
          2. Application
             1. HIV
             2. Hepatitis
             3. Influenza
       3. South Korea
       4. Japan
       5. India
       6. Australia
       7. Singapore
       8. Taiwan
       9. South East Asia
       10. Rest of Asia-Pacific
    5. Middle East and Africa
       1. Market Size and Forecast
          1. Drug Class
             1. DNA Polymerase Inhibitors
             2. Reverse Transcriptase Inhibitors
             3. Protease Inhibitors
          2. Application
             1. HIV
             2. Hepatitis
             3. Influenza
       2. UAE
          1. Drug Class
             1. DNA Polymerase Inhibitors
             2. Reverse Transcriptase Inhibitors
             3. Protease Inhibitors
          2. Application
             1. HIV
             2. Hepatitis
             3. Influenza
       3. Turkey
       4. Saudi Arabia
       5. South Africa
       6. Egypt
       7. Nigeria
       8. Rest of MEA
    6. LATAM
       1. Market Size and Forecast
          1. Drug Class
             1. DNA Polymerase Inhibitors
             2. Reverse Transcriptase Inhibitors
             3. Protease Inhibitors
          2. Application
             1. HIV
             2. Hepatitis
             3. Influenza
       2. Brazil
          1. Drug Class
             1. DNA Polymerase Inhibitors
             2. Reverse Transcriptase Inhibitors
             3. Protease Inhibitors
          2. Application
             1. HIV
             2. Hepatitis
             3. Influenza
       3. Mexico
       4. Argentina
       5. Chile
       6. Colombia
       7. Rest of LATAM
12. Competitive Landscape, 2025
    1. Introduction
    2. Antiviral Drug Market Share Analysis, 2025 (%)
       1. Market Share Analysis, 2025
       2. Competition Ranking, 2025
       3. Key Developments & Growth Strategies
          1. Merger & Acquisition
          2. Product Launch
          3. Expansion
       4. Consolidated SWOT Analysis of Key Players
13. Company Profile
    1. Gilead Sciences, Inc.
       1. Business Overview
       2. Financial Data
       3. Key Product domains
       4. Recent Developments
    2. GlaxoSmithKline plc
    3. Merck & Co., Inc.
    4. F. Hoffmann-La Roche Ltd.
    5. Johnson & Johnson
    6. Bristol Myers Squibb
    7. AbbVie Inc.
    8. Pfizer Inc.
    9. AstraZeneca plc
    10. Cipla Limited